Complete response letter received for avt02 biologics license application

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) announced that the u.s. food and drug administration (fda) has issued a complete response letter (crl) to its partner alvotech (nasdaq: alvo) for the biologics license application (bla) for avt02, a high-concentration biosimilar candidate for humira® (adalimumab).
ALVO Ratings Summary
ALVO Quant Ranking